Chapter

When Bioinformatics Meets Agent-Based Modeling: An Evolving Paradigm for Complex Biological Systems

Giulia Russo and Francesco Pappalardo

Abstract

Bioinformatics and agent-based modeling (ABM) represent a transformative integration for exploring and simulating complex biological systems. By combining computational models with diverse biological datasets, these approaches address intricate dynamic behaviors spanning molecular to population levels. This chapter delineates the foundational principles of bioinformatics and ABM, explores their integration strategies, and discusses the computational tools that facilitate this synergy. Case studies illustrate applications in immunotherapy optimization, immunotoxicant dynamics, and vaccine design, showcasing their relevance in advancing precision medicine and drug discovery. Key challenges, including data standardization, computational scalability, and model validation, are discussed alongside future directions. The chapter underscores the pivotal role of interdisciplinary collaborations and emerging technologies, such as artificial intelligence (AI) and quantum computing, in overcoming existing barriers and driving innovation in this field. Additionally, a special focus will be devoted to the evolving regulatory landscape that is starting to incorporate these innovative tools.

Keywords: bioinformatics, agent-based modeling, complex systems, computational biology, systems biology

1. Introduction

Bioinformatics has revolutionized the analysis of biological data, offering sophisticated tools to decode vast datasets from genomics, proteomics, and metabolomics [1, 2]. Concurrently, Agent-based modeling (ABM) has emerged as a powerful methodology to simulate individual entities and their interactions, elucidating emergent behaviors in complex systems [3, 4]. Integrating these fields enables innovative solutions for studying intricate biological phenomena [5].

Recent advancements in bioinformatics, including high-throughput sequencing and systems biology approaches, have enabled unprecedented exploration of molecular mechanisms underlying diseases [6, 7]. For instance, comprehensive protocols for investigating potential vaccine targets in pathogens like SARS-CoV-2 have been developed [8], combining transcriptomics and immunoinformatics to streamline influenza vaccine design [9].

Moreover, incorporating ABM in these analyses has allowed researchers to dynamically simulate immune responses, as demonstrated in studies predicting allergic reactions to chemical sensitizers [10]. These integrated approaches not only enhance predictive power but also reduce experimental costs and ethical concerns [11].

The synergy of bioinformatics and ABM is further highlighted in the context of immune system simulations [12]. By leveraging computational tools, researchers can predict the efficacy of therapeutic interventions, as shown in the development of multi-epitope vaccines for complex diseases like influenza [13]. This paradigm shift underscores the transformative potential of combining molecular insights with agent-based methodologies to address challenges in precision medicine and systems biology [14].

2. Core concepts and framework

2.1 Bioinformatics: An overview

Bioinformatics applies computational methods to manage, analyze, and interpret biological data [15]. The field has expanded significantly with the advent of next-generation sequencing (NGS) technologies, enabling high-resolution analysis of genomic and transcriptomic datasets [6]. These data provide insights into gene expression, regulatory networks, and epigenetic modifications [16, 17], paving the way for advancements in systems biology and personalized medicine.

Bioinformatics tools such as Cytoscape [18], STRING [19], and Reactome [20] provide valuable resources for annotating and visualizing molecular interactions. Additionally, machine learning algorithms integrated into platforms like DeepCell [21] have enhanced predictive accuracy, facilitating seamless integration into ABM studies.

A notable application of bioinformatics is in the design and evaluation of vaccines [22]. For example, transcriptomic analyses have identified key immune response pathways, aiding the development of multi-epitope vaccines targeting pathogens like SARS-CoV-2 [9, 13]. These approaches have been complemented by immunoinformatics tools that predict antigenicity and population coverage, ensuring broader vaccine efficacy [23].

Additionally, bioinformatics plays a critical role in drug discovery [24]. Researchers can identify novel therapeutic targets and repurpose existing drugs by integrating gene expression data with pathway analysis [25]. Studies on differential gene expression during disease progression have uncovered biomarkers that inform diagnostic and prognostic strategies [26].

Another area of focus is immunotoxicology [27], where bioinformatics methods are used to assess the impact of environmental chemicals on immune systems [28]. Tools like the Universal Immune System Simulator (UISS) [29, 30] have been employed to model immunotoxicity induced by skin sensitizers [10, 31], demonstrating the capability of bioinformatics to bridge data-driven insights and mechanistic understanding [32].

These advancements underscore the versatility of bioinformatics in addressing complex biological questions [33], from understanding molecular mechanisms to optimizing therapeutic strategies [34–38].

2.2 Agent-based modeling in biomedicine

ABM is a computational approach used to simulate the actions and interactions of individual agents within a system to assess their effects on the system as a whole [3, 4, 39–41]. Agents can represent cells, molecules, or even entire organisms in biological contexts. By modeling interactions at the individual level, ABM can capture emergent phenomena that are difficult to predict using traditional modeling techniques [5].

ABM is particularly valuable in studying systems with heterogeneous components and stochastic behaviors [42, 43], such as immune responses [44, 45], disease spread [46], and cellular dynamics [47, 48]. For instance, ABM has been utilized to model tumor growth and its microenvironment [49], capturing the complex interplay between cancer cells, stromal cells, and the immune system [50]. This has provided insights into tumor evolution [51] and potential therapeutic strategies [52].

Another application of ABM is in epidemiology, where it has been used to simulate the spread of infectious diseases and evaluate intervention strategies [53, 54]. By incorporating spatial and temporal dynamics, ABM can predict the impact of vaccination campaigns or quarantine measures, offering a flexible tool for public health planning [55–57].

The STriTuVaD project is an excellent example of ABM's utility. It has been applied to simulate the immune response to tuberculosis vaccines [45, 58, 59]. These models incorporate individual variability, enabling predictions of vaccine efficacy across diverse populations. Additionally, ABM has proven instrumental in ecological studies, modeling the interactions within microbial communities to understand their responses to environmental changes [60, 61].

As computational power grows, ABM becomes increasingly sophisticated, incorporating more detailed biological data and complex interaction rules [62, 63]. This advancement allows for more accurate and predictive simulations, bridging the gap between theoretical models and real-world applications [64].

2.3 Integrating bioinformatics with ABM

Integrating bioinformatics and ABM enables researchers to bridge molecular-level insights and system-level behaviors [65]. By combining large-scale omics data with dynamic modeling [66], this approach provides a comprehensive framework for understanding biological complexity and predicting outcomes of therapeutic interventions [67–69].

One key advancement in this integration is using multiscale models that incorporate genomic, proteomic, and metabolic data into ABM frameworks [40, 70]. For example, a recent study demonstrated the potential of combining transcriptomic data with ABM to predict the efficacy of drug treatments in heterogeneous populations [42]. Such models account for individual variability, enabling the design of personalized medicine strategies.

Educational initiatives have also emerged to promote integrating bioinformatics and ABM approaches. These efforts aim to train researchers in combining data-driven insights with mechanistic modeling, ensuring the next generation of scientists can leverage these tools effectively [71].

Another significant development is the application of integrated bioinformatics-ABM frameworks to study immune system dynamics [72]. By simulating immune responses using agent-based approaches informed by bioinformatics data, researchers can predict the efficacy of vaccines and identify potential side effects [22].



Figure 1.
Integration of bioinformatics and agent-based modeling (ABM), demonstrating the workflow from data acquisition to simulation outcomes for applications in precision medicine and vaccine design.

This methodology has been pivotal in accelerating the development of COVID-19 vaccines, demonstrating the real-world impact of this integration [73].

The combination of bioinformatics and ABM is also facilitating advancements in synthetic biology. For instance, models integrating gene regulatory networks and cellular dynamics have been used to design synthetic circuits with desired behaviors [74]. These innovations highlight the potential of integrated modeling approaches to drive fundamental research and applied sciences breakthroughs.

The integration of bioinformatics and ABM is visually summarized in the schematic diagram and flowchart provided below (**Figure 1**). These figures illustrate the data flow from acquisition through processing, leading to simulation and predictions, highlighting the dynamic interplay between data-driven bioinformatics and the mechanistic insights offered by agent-based modeling.

3. Case studies

The practical application of bioinformatics and ABM offers transformative insights into complex biological phenomena. This section highlights three case studies demonstrating this integration's utility: simulating the immune response to influenza, exploring allergic reactions to chemical sensitizers, and developing SARS-CoV-2 vaccine targets. These examples emphasize the versatility of these approaches in addressing diverse challenges in systems biology and medicine.

3.1 Modeling influenza: Merging bioinformatics and ABM for precision insights

This case study explores how the Universal Immune System Simulator (UISS) was utilized to simulate immune responses to influenza, as detailed in Pappalardo et al. [68]. UISS, an advanced ABM platform, incorporated multiscale data to model the intricate dynamics of host-pathogen interactions during influenza infection.

Combining bioinformatics with ABM protocols, the simulations provided insights into the effectiveness of different vaccine strategies by modeling antigen presentation, T-cell activation, and antibody production. For instance, the study demonstrated how adjuvants influenced the strength and duration of the immune response. Additionally, the model predicted population-level impacts of vaccination under various scenarios, helping to optimize immunization strategies [9, 30]. These findings highlight the synergistic role of bioinformatics and ABM in guiding influenza vaccine development and public health decision-making.

3.2 Simulating allergy pathways: Fusion of data-driven and agent-based models

A novel study [10] utilized ABM and bioinformatics to investigate skin and respiratory allergic reactions to chemical sensitizers. By integrating transcriptomic and proteomic data, the researchers modeled the activation of immune cells in response to chemical exposure, focusing on dendritic cell maturation and T-cell proliferation.

Using bioinformatics and ABM protocols, the simulations explored how different chemical structures triggered varying levels of immune sensitization, leading to allergic reactions [75]. The study also assessed the efficacy of potential therapeutic interventions, such as cytokine inhibitors, in mitigating these responses. By predicting the allergenic potential of new chemicals, this approach provides a valuable tool for regulatory agencies and industries aiming to develop safer consumer products. This case study underscores the critical role of integrated bioinformatics and ABM in advancing personalized approaches to managing and preventing allergic diseases [31, 76].

3.3 Targeting SARS-CoV-2 with combined bioinformatics and ABM approaches

The final case study examines how integrated approaches have streamlined vaccine development processes specifically targeting SARS-CoV-2. Researchers have accelerated the timeline for vaccine candidates by utilizing bioinformatics to identify immunodominant epitopes and ABM to predict population-level efficacy [8].

The combined protocols of bioinformatics and ABM proved invaluable in simulating herd immunity thresholds and optimizing adjuvant formulations. These methodologies demonstrated the potential to reduce dependency on animal testing, align with ethical considerations, and lower development costs. Moreover, integrating large-scale genomic and immunological data allowed for the design of vaccines that target specific viral vulnerabilities, advancing the precision of SARS-CoV-2 vaccine development [77, 78].

4. The regulatory aspect

The regulatory landscape surrounding the integration of bioinformatics and agent-based modeling (ABM) into biological research and clinical applications is evolving, driven by the increasing recognition of these tools as essential components of modern biomedical innovation. Regulatory agencies, such as the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA), are progressively embracing computational models for applications ranging from drug development to personalized medicine [79–81]. This shift has been supported by frameworks like the FDA's "Model-Informed Drug Development (MIDD)" initiative [82] and the EMA's efforts to incorporate in silico methods into the approval processes for new therapies [83]. However, these advancements bring unique challenges, particularly for ABMs, which differ from traditional modeling approaches due to their stochastic nature and the high granularity of individual-agent interactions [84].

To achieve regulatory acceptance, ABMs must undergo rigorous validation and standardization [85]. This involves demonstrating their reproducibility and alignment with experimental or clinical data and ensuring transparency in their assumptions, parameterization, and decision-making processes [86]. Recent state-of-the-art advancements have proposed Good Simulation Practices (GSP) as a pathway to guide the validation of computational models [87], including ABMs, in a manner that meets regulatory expectations [88]. These practices prioritize traceability and robustness and employ benchmark datasets to authenticate predictive outputs [89]. For bioinformatics data, integration into ABM frameworks raises additional concerns, particularly around data provenance, quality, and compliance with privacy regulations such as the General Data Protection Regulation (GDPR) [90]. Ensuring the ethical use of patient-derived data and the ability to audit and replicate simulations are increasingly critical for regulatory approval [91].

Emerging technologies are also reshaping the regulatory landscape. For instance, artificial intelligence (AI) and machine learning are leveraged to enhance model validation processes, optimize parameter fitting, and assess predictive accuracy [92]. Recent advances in explainable AI (XAI) offer tools to address the "black-box" nature of complex ABMs, making their predictions and underlying mechanisms more interpretable and aligned with regulatory requirements [93]. Furthermore, efforts to create harmonized regulatory guidelines for in silico trials, such as those spearheaded by the Virtual Physiological Human (VPH) Institute [94] and renowned research group, provide a foundation for systematically integrating bioinformatics and ABMs into decision-making frameworks for new therapies and interventions [58, 95, 96].

A critical frontier lies in establishing regulatory acceptance of multiscale ABMs incorporating bioinformatics data at molecular, cellular, and population levels. These models aim to bridge the gap between genomic insights and system-wide dynamics and are increasingly recognized for their potential to accelerate drug development and refine clinical trial designs. For instance, in silico trials that use integrated bioinformatics-ABM approaches to simulate patient populations can reduce the dependency on animal testing and lower development costs while maintaining ethical and scientific rigor [97].

The future of regulatory engagement with bioinformatics and ABM will depend heavily on fostering interdisciplinary collaboration among computational scientists, biologists, clinicians, and regulators. Transparent reporting standards, clear documentation of model assumptions and limitations, and continuous dialog with regulatory bodies will be essential to ensure these tools meet both scientific and regulatory expectations. By aligning advancements in computational modeling with regulatory requirements, the bioinformatics-ABM paradigm is poised to become a cornerstone of precision medicine, synthetic biology, and other fields where complex biological systems demand innovative and ethical solutions.

5. Challenges and future directions

Integrating bioinformatics and agent-based modeling (ABM) offers transformative potential for studying complex biological systems, yet it confronts significant challenges that must be surmounted to harness its impact [98] fully. These challenges include data standardization, computational scalability, and model validation [99, 100].

One major obstacle is the lack of data standardization and interoperability [101]. Integrating heterogeneous datasets from diverse sources—spanning genomic, proteomic, and metabolic information—frequently encounters issues of inconsistent annotations and variable experimental conditions [102]. This variability complicates their incorporation into ABM frameworks and limits the reproducibility of results [103]. Efforts to harmonize omics data with ABM frameworks are imperative, necessitating universal standards in bioinformatics tools to streamline data preprocessing and enhance model accuracy [104].

Moreover, the computational demands of ABM, especially when modeling large-scale systems or incorporating multiscale data, are substantial. These simulations often require significant memory and processing power, potentially hindering scalability [105] and the broader adoption of these methods. Recent advancements in cloud-based platforms and parallel computing [106], such as leveraging high-performance computing clusters [107], have begun to address these challenges by enabling the simulation of large-scale agent interactions, as demonstrated in studies of immune response dynamics [108].

Robust validation methods are required to ensure the reliability of integrated bioinformatics-ABM models [109]. Transparent reporting of model assumptions, parameter values, and performance metrics ensures reproducibility and encourages broader adoption.

Further addressing these computational and analytical demands, advances in bioinformatics have been instrumental. Enhanced by advanced machine learning techniques and high-performance computing [110], these improvements enable the development of more robust and interpretable models. Collaborative platforms that foster interdisciplinary efforts are also crucial for future advancements [111]. As we look forward, interdisciplinary collaborations will be pivotal in overcoming existing challenges. Additionally, emerging technologies such as quantum computing and AI-driven optimization offer promising solutions to computational bottlenecks [1, 92, 112]. Expanding the scope of applications to include areas like synthetic biology [113] and ecosystem modeling [114] could also unlock new frontiers for integrating bioinformatics and ABM.

6. Conclusions

Integrating bioinformatics and ABM has revealed a robust framework for unraveling the complexities of biological systems, providing multiscale insights by merging data-driven methodologies with dynamic simulations. The chapter has highlighted various applications, including immunotherapy optimization, host-microbiome interactions, and vaccine development, illustrating the practical impact of this integrated approach in medicine and biology. Despite its vast potential, the field faces significant challenges. Data standardization remains a major hurdle, complicating the integration of heterogeneous datasets and impacting reproducibility. The computational intensity of ABM also poses scalability challenges, although recent advances in cloud computing and high-performance computing have begun to mitigate these issues. Furthermore, ensuring the validity of models through robust validation protocols is crucial for their broader acceptance and application. This necessity aligns with the evolving regulatory perspective that increasingly acknowledges the importance of computational models in biomedical applications, as highlighted by initiatives like the FDA's Model-Informed Drug Development (MIDD). The future of bioinformatics and ABM integration looks promising, driven by advancements in machine learning, quantum computing, and AI optimization. These technologies are poised further to enhance models' computational capabilities and interpretability. Continued efforts in fostering interdisciplinary collaborations will be vital in overcoming existing challenges and unlocking new potential. By leveraging these advancements, bioinformatics and ABM can significantly contribute to transformative research in medicine, ecology, and beyond, paving the way for innovative solutions to complex biological challenges while adhering to regulatory standards.

Conflict of interest

The authors declare no conflict of interest.

Notes/thanks/other declarations

None.

Author details

Giulia Russo and Francesco Pappalardo*
Department of Drug and Health Sciences, University of Catania, Catania, Italy

*Address all correspondence to: francesco.pappalardo@unict.it

References

[1] Jamialahmadi H, Khalili-Tanha G, Nazari E, Rezaei-Tavirani M. Artificial intelligence and bioinformatics: A journey from traditional techniques to smart approaches. Gastroenterology and Hepatology from Bed to Bench. 2024;**17**(3):241-252. DOI: 10.22037/ghfbb.v17i3.2977

[2] Clark AJ, Lillard JW. A comprehensive review of bioinformatics tools for genomic biomarker discovery driving precision oncology. Genes. 2024;**15**(8):1036

[3] Bonabeau E. Agent-based modeling: Methods and techniques for simulating human systems. Proceedings of the National Academy of Sciences. 2002;**99**(Suppl. 3):7280-7287

[4] Cosgrove J, Butler J, Alden K, Read M, Kumar V, Cucurull-Sanchez L, et al. Agent-based modeling in systems pharmacology: Agent-based modeling in systems pharmacology. CPT: Pharmacometrics & Systems Pharmacology. 2015;**4**(11):615-629

[5] Merelli E, Armano G, Cannata N, Corradini F, d'Inverno M, Doms A, et al. Agents in bioinformatics, computational and systems biology. Briefings in Bioinformatics. 2006;**8**(1):45-59

[6] Satam H, Joshi K, Mangrolia U, Waghoo S, Zaidi G, Rawool S, et al. Next-generation sequencing technology: Current trends and advancements. Biology. 2023;**12**(7):997

[7] Vitorino R. Transforming clinical research: The power of high-throughput omics integration. Proteomes. 2024;**12**(3):25

[8] Russo G, Di Salvatore V, Sgroi G, Parasiliti Palumbo GA, Reche PA, Pappalardo F. A multi-step and multi-scale bioinformatic protocol to investigate potential SARS-CoV-2 vaccine targets. Briefings in Bioinformatics. 2022;**23**(1):bbab403

[9] Maleki A, Russo G, Parasiliti Palumbo GA, Pappalardo F. In silico design of recombinant multi-epitope vaccine against influenza A virus. BMC Bioinformatics. 2021;**22**:617. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85124104006&doi=10.1186%2fs12859-022-04581-6&partnerID=40&md5=a0bb68053aa51ee6054a41ffe0614fdf

[10] Russo G, Crispino E, Casati S, Corsini E, Worth A, Pappalardo F. Pioneering bioinformatics with agent-based modelling: An innovative protocol to accurately forecast skin or respiratory allergic reactions to chemical sensitizers. Briefings in Bioinformatics. 2024;**25**(6):bbae506

[11] Tsou AY, Graf WD, Russell JA, Epstein LG, On behalf of the Ethics, Law, and Humanities Committee, a joint committee of the American Academy of Neurology (AAN), American Neurological Association (ANA), et al. Ethical perspectives on costly drugs and health care: AAN position statement. Neurology. 2021;**97**(14):685-692

[12] Pappalardo F, Russo G, Reche PA. Toward computational modelling on immune system function. BMC Bioinformatics. 2020;**21**(S17):546, s12859-020-03897-5

[13] Momajadi L, Khanahmad H, Mahnam K. Designing a multi-epitope influenza vaccine: An immunoinformatics approach. Scientific Reports. 2024;**14**(1):25382

[14] Ponnarengan H, Rajendran S, Khalkar V, Devarajan G, Kamaraj L. Data-driven healthcare: The role of computational methods in medical innovation. Computer Modeling in Engineering and Sciences. 2025;**142**(1):1-48

[15] Bayat A. Science, medicine, and the future: Bioinformatics. BMJ. 2002;**324**(7344):1018-1022

[16] Sonawane AR, DeMeo DL, Quackenbush J, Glass K. Constructing gene regulatory networks using epigenetic data. npj Systems Biology and Applications. 2021;**7**(1):45

[17] Fritz AJ, El Dika M, Toor RH, Rodriguez PD, Foley SJ, Ullah R, et al. Epigenetic-mediated regulation of gene expression for biological control and cancer: Cell and tissue structure, function, and phenotype. In: Kloc M, Kubiak JZ, editors. Nuclear, Chromosomal, and Genomic Architecture in Biology and Medicine, Results and Problems in Cell Differentiation. Vol. 70. Cham: Springer International Publishing; 2022. pp. 339-373. Available from: https://link.springer.com/10.1007/978-3-031-06573-6_12

[18] Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, et al. Cytoscape: A software environment for integrated models of biomolecular interaction networks. Genome Research. 2003;**13**(11):2498-2504

[19] Szklarczyk D, Gable AL, Nastou KC, Lyon D, Kirsch R, Pyysalo S, et al. The STRING database in 2021: Customizable protein–protein networks, and functional characterization of user-uploaded gene/measurement sets. Nucleic Acids Research. 2021;**49**(D1):D605-D612

[20] Croft D, O'Kelly G, Wu G, Haw R, Gillespie M, Matthews L, et al. Reactome: A database of reactions, pathways and biological processes. Nucleic Acids Research. 2011;**39**(Database):D691-D697

[21] Greenwald NF, Miller G, Moen E, Kong A, Kagel A, Dougherty T, et al. Whole-cell segmentation of tissue images with human-level performance using large-scale data annotation and deep learning. Nature Biotechnology. 2022;**40**(4):555-565

[22] OladipoEK,AdeniyiMO,OgunlowoMT, Irewolede BA, Adekanola VO, Oluseyi GS, et al. Bioinformatics designing and molecular modelling of a universal mRNA vaccine for SARS-CoV-2 infection. Vaccine. 2022;**10**(12):2107

[23] Sarvmeili J, Baghban Kohnehrouz B, Gholizadeh A, Shanehbandi D, Ofoghi H. Immunoinformatics design of a structural proteins driven multi-epitope candidate vaccine against different SARS-CoV-2 variants based on fynomer. Scientific Reports. 2024;**14**(1):10297

[24] Somda D, Wilson Kpordze S, Jerpkorir M, Chantelle Mahora M, Wanjiru Ndungu J, Wambui Kamau S, et al. The role of bioinformatics in drug discovery: A comprehensive overview. In: Rudrapal M, editor. Pharmaceutical Science. IntechOpen; 2024. Available from: https://www.intechopen.com/chapters/88596

[25] Grimes T, Potter SS, Datta S. Integrating gene regulatory pathways into differential network analysis of gene expression data. Scientific Reports. 2019;**9**(1):5479

[26] Ajadee A, Mahmud S, Hossain MB, Ahmmed R, Ali MA, Reza MS, et al. Screening of differential gene expression patterns through survival analysis for diagnosis, prognosis and therapies of clear cell renal cell carcinoma. PLoS ONE. 2024;**19**(9):e0310843

[27] Germolec D, Luebke R, Rooney A, Shipkowski K, Vandebriel R, Van Loveren H. Immunotoxicology: A brief history, current status and strategies for future immunotoxicity assessment. Current Opinion in Toxicology. 2017;**5**:55-59

[28] Vos J, Van Loveren H, Wester P, Vethaak D. Toxic effects of environmental chemicals on the immune system. Trends in Pharmacological Sciences. 1989;**10**(7):289-292

[29] Pappalardo F, Pennisi M, Motta S. Universal immune system simulator framework (UISS). In: Proceedings of the First ACM International Conference on Bioinformatics and Computational Biology. Niagara Falls New York: ACM; 2010. pp. 649-650. Available from: https://dl.acm.org/doi/10.1145/1854776.1854900

[30] Russo G, Crispino E, Maleki A, Di Salvatore V, Stanco F, Pappalardo F. Beyond the state of the art of reverse vaccinology: Predicting vaccine efficacy with the universal immune system simulator for influenza. BMC Bioinformatics. 2023;**24**(1):231

[31] Russo G, Crispino E, Corsini E, Iulini M, Paini A, Worth A, et al. Computational modelling and simulation for immunotoxicity prediction induced by skin sensitisers. Computational and Structural Biotechnology Journal. 2022;**20**:6172-6181

[32] Olson RS, La Cava W, Mustahsan Z, Varik A, Moore JH. Data-driven advice for applying machine learning to bioinformatics problems. arXiv. 2017. Available from: https://arxiv.org/abs/1708.05070

[33] Oulas A, Minadakis G, Zachariou M, Sokratous K, Bourdakou MM, Spyrou GM. Systems bioinformatics: Increasing precision of computational diagnostics and therapeutics through network-based approaches. Briefings in Bioinformatics. 2019;**20**(3):806-824

[34] Casotti MC, Meira DD, Alves LNR, Bessa BGDO, Campanharo CV, Vicente CR, et al. Translational bioinformatics applied to the study of complex diseases. Genes. 2023;**14**(2):419

[35] Van Camp PJ, Haslam DB, Porollo A. Bioinformatics approaches to the understanding of molecular mechanisms in antimicrobial resistance. International Journal of Molecular Sciences. 2020;**21**(4):1363

[36] Ramarajyam G, Murugan R, Rajendiran S. Network pharmacology and bioinformatics illuminates punicalagin's pharmacological mechanisms countering drug resistance in hepatocellular carcinoma. Human Genetics. 2024;**42**:201328

[37] Jiménez-Santos MJ, García-Martín S, Fustero-Torre C, Di Domenico T, Gómez-López G, Al-Shahrour F. Bioinformatics roadmap for therapy selection in cancer genomics. Molecular Oncology. 2022;**16**(21):3881-3908

[38] Ashik MAR, Hossain MA, Rahman SA, Akter MS, Zaman NN, Uddin MH, et al. Bioinformatics and system biology approaches for identifying potential therapeutic targets for prostate cancer. Informatics in Medicine Unlocked. 2024;**47**:101488

[39] Laubenbacher R, Hinkelmann F, Oremland M. Agent-based models and optimal control in biology: A discrete approach. In: Mathematical Concepts and Methods in Modern Biology. United States: Elsevier;

2013. pp. 143-178. Available from: https://linkinghub.elsevier.com/retrieve/pii/B9780124157804000053

[40] An G, Mi Q, Dutta-Moscato J, Vodovotz Y. Agent-based models in translational systems biology. WIREs Systems Biology and Medicine. 2009;**1**(2):159-171

[41] Cogno N, Axenie C, Bauer R, Vavourakis V. Agent-based modeling in cancer biomedicine: Applications and tools for calibration and validation. Cancer Biology & Therapy. 2024;**25**(1):2344600

[42] Yu JS, Bagheri N. Agent-based models predict emergent behavior of heterogeneous cell populations in dynamic microenvironments. Frontiers in Bioengineering and Biotechnology. 2020;**8**:249

[43] Bauer AL, Beauchemin CAA, Perelson AS. Agent-based modeling of host–pathogen systems: The successes and challenges. Information Sciences. 2009;**179**(10):1379-1389

[44] Xu Q, Ozturk MC, Cinar A. Agent-based modeling of immune response to study the effects of regulatory T cells in type 1 diabetes. Processes. 2018;**6**(9):141

[45] Russo G, Sgroi G, Parasiliti Palumbo GA, Pennisi M, Juarez MA, Cardona PJ, et al. Moving forward through the in silico modeling of tuberculosis: A further step with UISS-TB. BMC Bioinformatics. 2020;**21**(S17):458

[46] Kim Y, Cho N. A simulation study on spread of disease and control measures in closed population using ABM. Computation. 2022;**10**(1):2

[47] Dalmasso G, Marin Zapata PA, Brady NR, Hamacher-Brady A. Agent-based modeling of mitochondria links sub-cellular dynamics to cellular homeostasis and heterogeneity. PLoS ONE. 2017;**12**(1):e0168198

[48] Pleyer J, Fleck C. Agent-based models in cellular systems. Frontiers of Physics. 2023;**10**:968409

[49] Van Genderen MNG, Kneppers J, Zaalberg A, Bekers EM, Bergman AM, Zwart W, et al. Agent-based modeling of the prostate tumor microenvironment uncovers spatial tumor growth constraints and immunomodulatory properties. npj Systems Biology and Applications. 2024;**10**(1):20

[50] Gong C, Milberg O, Wang B, Vicini P, Narwal R, Roskos L, et al. A computational multiscale agent-based model for simulating spatio-temporal tumour immune response to PD1 and PDL1 inhibition. Journal of the Royal Society Interface. 2017;**14**(134):20170320

[51] Colyer B, Bak M, Basanta D, Noble R. A seven-step guide to spatial, agent-based modelling of tumour evolution. Evolutionary Applications. 2024;**17**(5):e13687

[52] Stephan S, Galland S, Labbani Narsis O, Shoji K, Vachenc S, Gerart S, et al. Agent-based approaches for biological modeling in oncology: A literature review. Artificial Intelligence in Medicine. 2024;**152**:102884

[53] Thomopoulos V, Tsichlas K. An agent-based model for disease epidemics in Greece. Information. 2024;**15**(3):150

[54] Bissett KR, Cadena J, Khan M, Kuhlman CJ. Agent-based computational epidemiological modeling. Journal of the Indian Institute of Science. 2021;**101**(3):303-327

[55] Sulis E, Terna P. An agent-based decision support for a vaccination

campaign. Journal of Medical Systems. 2021;**45**(11):97

[56] Wang P, Zheng X, Liu H. Simulation and forecasting models of COVID-19 taking into account spatio-temporal dynamic characteristics: A review. Frontiers in Public Health. 2022;**10**:1033432

[57] Cattaneo A, Vitali A, Mazzoleni M, Previdi F. An agent-based model to assess large-scale COVID-19 vaccination campaigns for the Italian territory: The case study of Lombardy region. Computer Methods and Programs in Biomedicine. 2022;**224**:107029

[58] Juárez MA, Pennisi M, Russo G, Kiagias D, Curreli C, Viceconti M, et al. Generation of digital patients for the simulation of tuberculosis with UISS-TB. BMC Bioinformatics. 2020;**21**(S17):449

[59] Pennisi M, Russo G, Sgroi G, Bonaccorso A, Parasiliti Palumbo GA, Fichera E, et al. Predicting the artificial immunity induced by RUTI® vaccine against tuberculosis using universal immune system simulator (UISS). BMC Bioinformatics. 2019;**20**(S6):504

[60] Bengtsson-Palme J. Microbial model communities: To understand complexity, harness the power of simplicity. Computational and Structural Biotechnology Journal. 2020;**18**:3987-4001

[61] Nagarajan K, Ni C, Lu T. Agent-based modeling of microbial communities. ACS Synthetic Biology. 2022;**11**(11):3564-3574

[62] Puniya BL, Verma M, Damiani C, Bakr S, Dräger A. Perspectives on computational modeling of biological systems and the significance of the SysMod community. Bioinformatics Advances. 2024;**4**(1):vbae090

[63] Sun Z, Lorscheid I, Millington JD, Lauf S, Magliocca NR, Groeneveld J, et al. Simple or complicated agent-based models? A complicated issue. Environmental Modelling and Software. 2016;**86**:56-67

[64] Jain HV, Norton KA, Prado BB, Jackson TL. SMoRe ParS: A novel methodology for bridging modeling modalities and experimental data applied to 3D vascular tumor growth. Frontiers in Molecular Biosciences. 2022;**9**:1056461

[65] Ji Z, Yan K, Li W, Hu H, Zhu X. Mathematical and computational modeling in complex biological systems. BioMed Research International. 2017;**2017**:1-16

[66] Sanches PHG, De Melo NC, Porcari AM, De Carvalho LM. Integrating molecular perspectives: Strategies for comprehensive multi-omics integrative data analysis and machine learning applications in transcriptomics, proteomics, and metabolomics. Biology. 2024;**13**(11):848

[67] Ponce-de-Leon M, Montagud A, Noël V, Meert A, Pradas G, Barillot E, et al. PhysiBoSS 2.0: A sustainable integration of stochastic Boolean and agent-based modelling frameworks. npj Systems Biology and Applications. 2023;**9**(1):54

[68] Pennisi M, Russo G, Ravalli S, Pappalardo F. Combining agent based-models and virtual screening techniques to predict the best citrus-derived vaccine adjuvants against human papilloma virus. BMC Bioinformatics. 2017;**18**:544. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85039714188&doi=10.1186%2fs12859-017-1961-9&partnerID=40&md5=79ec977bd7341043e31d717316526cbc

[69] Pennisi M, Russo G, Pappalardo F. Combining parallel genetic algorithms

and machine learning to improve the research of optimal vaccination protocols. In: Proceedings—26th Euromicro International Conference on Parallel, Distributed, and Network-Based Processing, PDP 2018. Cambridge, United Kingdom: IEEE Computer Society; 2018. pp. 399-405. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85048768620&doi=10.1109%2fPDP2018.2018.00070&partnerID=40&md5=9c6406acd0accbdd0da014c8383d96e0

[70] Zhang L, Athale CA, Deisboeck TS. Development of a three-dimensional multiscale agent-based tumor model: Simulating gene-protein interaction profiles, cell phenotypes and multicellular patterns in brain cancer. Journal of Theoretical Biology. 2007;**244**(1):96-107

[71] Sivakumar N, Mura C, Peirce SM. Innovations in integrating machine learning and agent-based modeling of biomedical systems. Frontiers in Systems Biology. 2022;**2**:959665

[72] Jamali Y. Modeling the immune system through agent-based modeling: A mini-review. Immunoregulation. 2024;**6**(1):3-12

[73] Russo G, Di Salvatore V, Caraci F, Curreli C, Viceconti M, Pappalardo F. How can we accelerate COVID-19 vaccine discovery? Expert Opinion on Drug Discovery. 2021;**16**(10):1081-1084

[74] Rodrigo G, Carrera J, Jaramillo A. Computational design of synthetic regulatory networks from a genetic library to characterize the designability of dynamical behaviors. Nucleic Acids Research. 2011;**39**(20):e138

[75] Sutanto H. Mechanobiology of type 1 hypersensitivity: Elucidating the impacts of mechanical forces in allergic reactions. Mechanobiology in Medicine. 2024;**2**(1):100041

[76] Pappalardo F, Russo G, Corsini E, Paini A, Worth A. Translatability and transferability of in silico models: Context of use switching to predict the effects of environmental chemicals on the immune system. Computational and Structural Biotechnology Journal. 2022;**20**:1764-1777

[77] Ozsahin DU, Ameen ZS, Hassan AS, Mubarak AS. Enhancing explainable SARS-CoV-2 vaccine development leveraging bee colony optimised Bi-LSTM, Bi-GRU models and bioinformatic analysis. Scientific Reports. 2024;**14**(1):6737

[78] Russo G, Pennisi M, Fichera E, Motta S, Raciti G, Viceconti M, et al. In silico trial to test COVID-19 candidate vaccines: A case study with UISS platform. BMC Bioinformatics. 2020;**21**(S17):527

[79] Marques L, Costa B, Pereira M, Silva A, Santos J, Saldanha L, et al. Advancing precision medicine: A review of innovative in silico approaches for drug development, clinical pharmacology and personalized healthcare. Pharmaceutics. 2024;**16**(3):332

[80] Musuamba FT, Skottheim Rusten I, Lesage R, Russo G, Bursi R, Emili L, et al. Scientific and regulatory evaluation of mechanistic in silico drug and disease models in drug development: Building model credibility. CPT: Pharmacometrics & Systems Pharmacology. 2021;**10**(8):804-825

[81] Karanasiou G, Edelman E, Boissel FH, Byrne R, Emili L, Fawdry M, et al. Advancing in silico clinical trials for regulatory adoption and innovation. IEEE Journal of Biomedical and Health Informatics. 2024;**99**:1-15

[82] Madabushi R, Benjamin J, Zhu H, Zineh I. The US Food and Drug Administration's model-informed drug development meeting program: From pilot to pathway. Clinical Pharmacology and Therapeutics. 2024;**116**(2):278-281

[83] Giannuzzi V, Bertolani A, Torretta S, Reggiardo G, Toich E, Bonifazi D, et al. Innovative research methodologies in the EU regulatory framework: An analysis of EMA qualification procedures from a pediatric perspective. Frontiers in Medicine. 2024;**11**:1369547

[84] Curreli C, Pappalardo F, Russo G, Pennisi M, Kiagias D, Juarez M, et al. Verification of an agent-based disease model of human mycobacterium tuberculosis infection. International Journal of Numerical Methods in Biomedical Engineering. 2021;**37**(7):e3470. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85105674679&doi=10.1002%2fcnm.3470&partnerID=40&md5=302faed2cac478c377211534fc61d1a0

[85] Viceconti M, Pappalardo F, Rodriguez B, Horner M, Bischoff J, Musuamba TF. In silico trials: Verification, validation and uncertainty quantification of predictive models used in the regulatory evaluation of biomedical products. Methods. 2021;**185**:120-127

[86] Russo G, Parasiliti Palumbo GA, Pennisi M, Pappalardo F. Model verification tools: A computational framework for verification assessment of mechanistic agent-based models. BMC Bioinformatics. 2021;**22**:626. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85130388346&doi=10.1186%2fs12859-022-04684-0&partnerID=40&md5=2a18b4cb393b67b89965e08585764ea7

[87] Viceconti M, Juárez M, Loewe A, Calvetti D, Somersalo E, Geris L, et al. Theoretical foundations of good simulation practice. In: Viceconti M, Emili L, editors. Toward Good Simulation Practice, Synthesis Lectures on Biomedical Engineering. Cham: Springer Nature Switzerland; 2024. pp. 9-23. Available from: https://link.springer.com/10.1007/978-3-031-48284-7_2

[88] Viceconti M, Serigado A, Rousseau CF, Voisin EM. Possible qualification pathways for in silico methodologies. In: Viceconti M, Emili L, editors. Toward Good Simulation Practice, Synthesis Lectures on Biomedical Engineering. Cham: Springer Nature Switzerland; 2024. pp. 67-72. Available from: https://link.springer.com/10.1007/978-3-031-48284-7_5

[89] Courcelles E, Horner M, Afshari P, Kulesza A, Curreli C, Vaghi C, et al. Model credibility. In: Viceconti M, Emili L, editors. Toward Good Simulation Practice, Synthesis Lectures on Biomedical Engineering. Cham: Springer Nature Switzerland; 2024. pp. 43-66. Available from: https://link.springer.com/10.1007/978-3-031-48284-7_4

[90] Alkhatib R, Gaede KI. Data management in biobanking: Strategies, challenges, and future directions. Biotech. 2024;**13**(3):34

[91] Khatiwada P, Yang B, Lin JC, Blobel B. Patient-generated health data (PGHD): Understanding, requirements, challenges, and existing techniques for data security and privacy. Journal of Personalized Medicine. 2024;**14**(3):282

[92] Huanbutta K, Burapapadh K, Kraisit P, Sriamornsak P, Ganokratanaa T, Suwanpitak K, et al. Artificial intelligence-driven pharmaceutical industry: A paradigm shift in drug discovery, formulation development,

manufacturing, quality control, and post-market surveillance. European Journal of Pharmaceutical Sciences. 2024;**203**:106938

[93] Sharma NA, Chand RR, Buksh Z, Ali ABMS, Hanif A, Beheshti A. Explainable AI frameworks: Navigating the present challenges and unveiling innovative applications. Algorithms. 2024;**17**(6):227

[94] Viceconti M, Clapworthy G, Jan SVS. The virtual physiological human—A European initiative for in silico human modelling. The Journal of Physiological Sciences. 2008;**58**(7):441-446

[95] Cassidy R, Singh NS, Schiratti PR, Semwanga A, Binyaruka P, Sachingongu N, et al. Mathematical modelling for health systems research: A systematic review of system dynamics and agent-based models. BMC Health Services Research. 2019;**19**(1):845

[96] Dotolo S, Marabotti A, Rachiglio AM, Esposito Abate R, Benedetto M, Ciardiello F, et al. A multiple network-based bioinformatics pipeline for the study of molecular mechanisms in oncological diseases for personalized medicine. Briefings in Bioinformatics. 2021;**22**(6):bbab180

[97] Pappalardo F, Russo G, Tshinanu FM, Viceconti M. In silico clinical trials: Concepts and early adoptions. Briefings in Bioinformatics. 2019;**20**(5):1699-1708

[98] Cilfone NA, Kirschner DE, Linderman JJ. Strategies for efficient numerical implementation of hybrid multi-scale agent-based models to describe biological systems. Cellular and Molecular Bioengineering. 2015;**8**(1):119-136

[99] Yang A, Troup M, Ho JWK. Scalability and validation of big data bioinformatics software. Computational and Structural Biotechnology Journal. 2017;**15**:379-386

[100] Vermeer WH, Smith JD, Wilensky U, Brown CH. High-Fidelity agent-based modeling to support prevention decision-making: An open science approach. Prevention Science. 2022;**23**(5):832-843

[101] Lopez Poncelas M, La Barbera L, Rawlinson JJ, Crandall D, Aubin CE. Credibility assessment of patient-specific biomechanical models to investigate proximal junctional failure in clinical cases with adult spine deformity using ASME V&V40 standard. Computer Methods in Biomechanics and Biomedical Engineering. 2022;**25**(5):543-553

[102] Manzoni C, Kia DA, Vandrovcova J, Hardy J, Wood NW, Lewis PA, et al. Genome, transcriptome and proteome: The rise of omics data and their integration in biomedical sciences. Briefings in Bioinformatics. 2018;**19**(2):286-302

[103] Fitzpatrick BG. Issues in reproducible simulation research. Bulletin of Mathematical Biology. 2019;**81**(1):1-6

[104] Sen P, Orešič M. Integrating omics data in genome-scale metabolic modeling: A methodological perspective for precision medicine. Metabolites. 2023;**13**(7):855

[105] Lorig F, Dammenhayn N, Müller DJ, Timm IJ. Measuring and comparing scalability of agent-based simulation frameworks. In: Müller JP, Ketter W, Kaminka G, Wagner G, Bulling N, editors. Multiagent System Technologies. Cham: Springer International Publishing; 2015. pp. 42-60. Available from: http://link.springer.com/10.1007/978-3-319-27343-3_3

[106] Grelck C, Niewiadomska-Szynkiewicz E, Aldinucci M, Bracciali A, Larsson E. Why high-performance modelling and simulation for big data applications matters. In: Kołodziej J, González-Vélez H, editors. High-Performance Modelling and Simulation for Big Data Applications, Lecture Notes in Computer Science. Vol. 11400. Cham: Springer International Publishing; 2019. pp. 1-35. Available from: http://link.springer.com/10.1007/978-3-030-16272-6_1

[107] Chou J, Chung WC. Cloud computing and high performance computing (HPC) advances for next generation internet. Future Internet. 2024;**16**(12):465

[108] Christley S, Scarborough W, Salinas E, Rounds WH, Toby IT, Fonner JM, et al. VDJServer: A cloud-based analysis portal and data commons for immune repertoire sequences and rearrangements. Frontiers in Immunology. 2018;**9**:976

[109] Walpole J, Papin JA, Peirce SM. Multiscale computational models of complex biological systems. Annual Review of Biomedical Engineering. 2013;**15**(1):137-154

[110] Sovis A, Patikirige C, Pandigama Y. Enhanced timetable scheduling: A high-performance computational approach. In: 2023 8th International Conference on Information Technology Research (ICITR). Colombo, Sri Lanka: IEEE; 2023. pp. 1-6. Available from: https://ieeexplore.ieee.org/document/10382749/

[111] Patel AU, Gu Q, Esper R, Maeser D, Maeser N. The crucial role of interdisciplinary conferences in advancing explainable AI in healthcare. BioMedInformatics. 2024;**4**(2):1363-1383

[112] Durant TJS, Knight E, Nelson B, Dudgeon S, Lee SJ, Walliman D, et al. A primer for quantum computing and its applications to healthcare and biomedical research. Journal of the American Medical Informatics Association. 2024;**31**(8):1774-1784

[113] Matuszyńska A, Ebenhöh O, Zurbriggen MD, Ducat DC, Axmann IM. A new era of synthetic biology—Microbial community design. Synthetic Biology. 2024;**9**(1):ysae011

[114] Petrovskii S, Petrovskaya N. Computational ecology as an emerging science. Interface Focus. 2012;**2**(2):241-254